


To: Veronica Popo  
Department of Health  
MHRA  
Room 14-138 Market Towers  
1 Nine Elms Lane  
LONDON SW8 5NQ

From: British Association of Dermatologists  
4 Fitzroy Square \_\_\_\_\_  
London W1T 5HQ \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**CONSULTATION LETTER ARM 62  
LAMISIL ONCE 1% CUTANEOUS SOLUTION**

Request to Reclassify a Product from

- ~~\* 1. We have no comments to make on the proposals in ARM 62~~
- \* 2. Our comments on the proposals in ARM 62 are below/attached.
  - \*Our reply may be made freely available
  - ~~\*Our reply is confidential~~
  - ~~\*Our reply is partially confidential (indicate clearly in the text any confidential elements)~~



Signed: \_\_\_\_\_

\*Delete as appropriate

Date: 30<sup>th</sup> June 2009 \_\_\_\_\_

**Comments:**

The British Association of Dermatologists has no concerns about this reclassification from P to GSL, however we would like to make 2 points:

1. We have asked before if abbreviations such as "P" and "GSL", which are not known to all of us, could be explained in full in future consultations.
2. It is worth noting in the patient information that both eczema and psoriasis can mimic fungal foot infections and especially if it is fissured, topical Lamisil could worsen symptoms.